Now in its seventh year, the TIL Therapies Summit returns as the world’s leading event dedicated to advancing tumor-infiltrating lymphocyte (TIL) therapies. Taking place November 11–13, 2025, in ...
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback